🧬 5 terapias dirigidas innovadoras de China
🎯 5 mecanismos clave
🌍 1 objetivo: transformar el tratamiento del cáncer de pulmón

#CáncerDePulmón #CPNM #SaludPulmonar #TerapiaDirigida #Biotecnología #EGFR #ALK #ROS1 #Antiangiogénesis #PD1 #VEGF #InnovaciónChina #DengYueMedicinasEnHongKong

#HCC: 3 enfoques terapéuticos que están cambiando el panorama clínico
🔹 PD-1
🔹 Anti-VEGF
🔹 TKI

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#CarcinomaHepatocelular #InmunoOncología #AntiVEGF #TKI #PD1 #TerapiaSistémica #DengYueMedicinasEnHongKong

🎯 4 dianas clave.
🧬 Tratamiento de precisión.
🌍 Impacto global.

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#CáncerDePulmón #CáncerDePulmónNoMicrocítico #NSCLC #Oncología #OncologíaClínica #SaludGlobal #EGFR #ALK #PD1 #PDL1 #KRAS #KRASG12C #DengYueMedicinasEnHongKong

Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform Statement of Significance: We discovered a common light chain (CLC) bispecific antibody targeting PD-1 and PD-L1 with favorable biophysical properties and

Antibody Therapeutics(IF=4.5, Oxford University Press)
🎯🎯Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
academic.oup.com/abt/article/...
#PD1 #PDL1 #YeastDisplay #Hybridoma

🩸 Additional insights on myeloma biology and microenvironment

#MultipleMyeloma #EquilibriumPhase #Immunotherapy #HEMEHUB #EscapePhase #PD1 #CTLA4 #BCells #HemeOnc #Hematology

Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling, offering new therapeutic strategies for inflammatory bowel disease.
doi.org/10.1038/s413...
#InflammatoryBowelDisease #TCells #ExtracellularVesicles #PD1 #Immunotherapy

Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial – Phio Pharmaceuticals Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 Responders No Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation Cohorts King of Prussia, Pennsylvania–(Newsfile Corp. – February 10, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a […] Read the full article here

Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial – Phio Pharmaceuticals Maximum Dose Concentration in Final Cohort Yiel...

#General #Medicine #News #PD1

Origin | Interest | Match

Dr. Jewett's review examines PD-1's contrasting roles: block it in cancer to boost immunity, enhance it in autoimmune diseases to suppress overactive responses.

Free until March 15: dl.begellhouse.com/journals/2ff...

#PD1 #Immunotherapy

Akeso Biopharma presenta la BLA de ivonescimab (anticuerpo biespecífico PD-1/VEGF) ante la FDA

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Oncología #CáncerDePulmón #NSCLC #CPNM #EGFR #PD1 #VEGF #AnticuerpoBiespecífico #Ivonescimab #SummitTherapeutics #FDA

💉 China aprueba #BecotatugVedotin
👩‍⚕️👨‍⚕️ Para pacientes adultos con:
• Cáncer de nasofaringe avanzado
– #PD1 / #PDL1
📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#ADC #CáncerDeCabezaYCuello #CáncerMetastásico #CáncerAvanzado #DengYueMedicinasEnHongKong

La NMPA de China aprueba condicionalmente las cápsulas de Tunlametinib

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Tunlametinib #Keluping #NMPA #China #Melanoma #NRAS #PD1 #PDL1 #InhibidorMEK #InnovaciónFarmacéutica #AprobaciónCondicional

Graphic with headshot of Nicole Mihalik, postdoctoral associate in Dario Vignali's lab at the University of Pittsburgh Department of Immunology, announcing her new F32 training grant from the National Cancer Institute for her project titled "Relative and synergistic contributions of PD1 and LAG3 on CD4+ T conventional cells in cancer."

Congratulations to Nicole Mihalik, postdoc in the @vignalilab.bsky.social, for being awarded an F32 fellowship from the National Cancer Institute to investigate how #PD1 and #LAG3 regulate CD4+ #Tcell exhaustion in #cancer! Read more: buff.ly/WM8Ajt3

Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A Multicenter, Retrospective Analysis The graphic abstract presents a retrospective study focused on lung cancer immunotherapy, carried out across five hospitals. It evaluates the efficacy of PD-1 versus PD-L1 inhibitors in treating non–...

#Article in #MedComm
Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A #Multicenter, #Retrospective Analysis doi.org/10.1002/mco2...

#immunotherapy #LungCancer #PD1 #PDL1

Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex Statement of Significance: IAP0971 is a novel bifunctional PD1/IL15 immunocytokine that has demonstrated excellent anti-tumor efficacy and favorable safety

High impact research (2023 Paper): "Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex" by Dr. Liusong Yin et al from SunHo.

doi.org/10.1093/abt/...

#PD1 #IL15 #Oncology

How do ILC1s help fight cancer, and what role does PD-1 play?

This open access review breaks down the complexity of ILC1 subsets and their checkpoint regulation.

📖 https://bit.ly/4fnU0N0

#ILC1 #CancerImmunology #PD1

Question remains, is the abscopal effect real? Or is #RT just additive? Certainly evidence for modifying TME, intriguing data for WNT-mt patients when adding #radiotherapy to #PD1 #immunotherapy, but the idea of #RT being a 'vaccine', expanding the immune repertoire, is shown in just 1-2 patients.

Using an IO dataset of #nivolumab-treated renal cancer patients, we found that:
- #PD1 or #PDL1 expression didn't predict survival
- PD1 activity (from RIDDEN) did associate with survival.
Showing that receptor activity could be a more effective biomarker than expression. 5/n

You can also hear the #PD1 story as told by CCII Director Tasuku Honjo on the @embo.org podcast

www.embo.org/podcasts/fro...

Unlocking LAG3: Ubiquitin’s unexpected role The inhibitory receptor LAG3 is the target of the FDA-approved mAb relatlimab, but its mechanism of signaling is not well understood. In this issue of Cell, Jiang et al. demonstrate that ubiquitinatio...

🔓 New #CellPreview by Prof. Kai W. Wucherpfennig @harvard.edu highlights our work on LAG3!

Key take:
• Cbl-mediated, non-degradative poly-ubiquitination at K498 unlocks LAG3 signaling
• Marks TILs that respond to PD-1/LAG3 combo

#LAG3 #Immunotherapy #PD1 #TCell
www.cell.com/cell/fulltex...

The Role of Immunotherapy in Salivary Gland Cancer: A Systematic Review - Feb 28, 2025
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cancertreatment #PD1 #anti-PD1 #openaccess

Targeting PD-1 in Rheumatoid Arthritis | RheumNow The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.The manufacturer, An...

“The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe #rheumatoidarthritis (RA) patients.”

#PD1 #arthritis #Rheumsky
@rheumnow.bsky.social

rheumnow.com/news/targeti...

www.ncbi.nlm.nih.gov/pmc/articles...

while #flubendazole, which belongs to the benzimidazole family, exerted similar effects on #STAT3, affecting #PD1 expression."

The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation - PubMed The incidence of melanoma is increasing faster than any other cancer. In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death p...

pubmed.ncbi.nlm.nih.gov/31128215/

"Most surprisingly, flubendazole inhibited #PD1 levels within the tumors, but not #PDL1."

The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation - PubMed The incidence of melanoma is increasing faster than any other cancer. In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death p...

The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation #PD1 #MECFS #LongCovid

pubmed.ncbi.nlm.nih.gov/31128215/

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differ...

pmc.ncbi.nlm.nih.gov/articles/PMC...

"Thus, #PD1 blockade worked after cessation of mTOR inhibition, but simultaneous treatment failed to induce functional TIM3+ cells, reducing efficacy of #PD1 immunotherapy."

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differ...

pmc.ncbi.nlm.nih.gov/articles/PMC...

"Mechanistically, a cell-intrinsic mTOR signal was vital for differentiation of stem-like T cells into the TIM3+ state in the early and late phases of chronic infection as well as during #PD1 immunotherapy."

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differ...

pmc.ncbi.nlm.nih.gov/articles/PMC...

"Blocking mTOR during the T cell expansion phase enhanced the T cell response by causing accumulation of stem-like T cells, leading to improved efficacy of #PD1 immunotherapy;"

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differ...

mTOR regulates T cell exhaustion and #PD1 –targeted immunotherapy response during chronic viral infection #MECFS #LongCovid

pmc.ncbi.nlm.nih.gov/articles/PMC...

Functional differences between rodent and human PD-1 linked to evolutionary divergence A highly conserved motif in human PD-1 but absent in rodent PD-1 is linked to differential inhibitory activity.

Takeya Masubuchi, Enfu Hui, et al. revealed functional differences between rodent and human #PD1 (an immune checkpoint), which is a target of cancer #immunotherapy,
in Science Immunology: www.science.org/doi/10.1126/...